Related Experiment Videos
Experience with aromatase inhibitors in the treatment of advanced breast cancer
1Klinik für Innere Medizin II, Friedrich-Schiller-Universität Jena, Germany.
Abstract:
Inhibition of the aromatase enzyme system has become an established means of hormonal treatment for hormone-responsive advanced breast cancer. The widest clinical experience is with aminoglutethimide, which achieves around 30% objective remissions of metastatic disease for up to 1 year. Due to the sometimes serious side-effects of this drug, preclinical and clinical investigations have been undertaken and have yielded a number of steroidal and non-steroidal aromatase inhibitors that have been shown in early or mature clinical trials to give objective disease remissions similar to those with aminoglutethimide but with less toxicity. There is thus good reason to believe that newer aromatase inhibiting drugs will soon be available for routine use in patients with breast cancer. This paper summarizes our experience and reviews data from other groups.
Insights
Newer aromatase inhibitors offer effective hormonal treatment for advanced breast cancer with reduced toxicity compared to aminoglutethimide. These drugs show promise for wider clinical use in breast cancer patients.
Area of Science:
- Endocrinology
- Oncology
- Pharmacology
Background:
- Aromatase enzyme inhibition is a key hormonal therapy for advanced breast cancer.
- Aminoglutethimide is widely used but associated with significant side effects.
- Research is ongoing to find safer and equally effective alternatives.
Purpose of the Study:
- To review the efficacy and toxicity of newer aromatase inhibitors.
- To summarize clinical trial data on novel aromatase inhibitors for breast cancer.
- To assess the potential of these agents for routine clinical practice.
Main Methods:
- Review of preclinical and clinical investigations.
- Analysis of data from early and mature clinical trials.
- Summary of institutional experience and published literature.
Main Results:
- Newer steroidal and non-steroidal aromatase inhibitors demonstrate objective remission rates comparable to aminoglutethimide.
- These novel agents exhibit a more favorable toxicity profile.
- Clinical trials indicate similar efficacy with improved tolerability.
Conclusions:
- Novel aromatase inhibitors are emerging as viable treatment options for hormone-responsive advanced breast cancer.
- Reduced toxicity makes these newer drugs a promising alternative to aminoglutethimide.
- These agents are expected to be available for routine use in breast cancer management.